NZE · TAH.NZ · NZD
Stock price, dividends, earnings
Quote as of Oct 30, 2026, 03:04 AM UTC. Cached market data; not a live quote.
One-year closing-price history · NZD. Historical prices are not a forecast.
Third Age Health Services Limited’s quoted price sits in the lower half of its reported 52-week range, 43.78% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
THE INCOME SIDE
Third Age Health Services Limited’s forward annual dividend is NZ$0.16 per share, paid quarterly. The forward yield is 3.81% at the quoted price. Future payments can change.
Historical amounts are adjusted for stock splits. Understand ex-dividend and payment dates →
BEHIND THE RESULTS
Upcoming dates and analyst estimates may change. Fiscal quarters follow Third Age Health Services Limited’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Third Age Health Services Limited, together with its subsidiaries, provides general practice health care services for older people living in retirement villages, private hospitals, and secure dementia units in New Zealand. The company offers aged medical residential care services, such as medical care services to the aged care sector; and general practice medical services, including primary care services to the community. It also provides onsite clinics, rostered rounds, and after hours on-call healthcare services for supporting the health and wellbeing of older people, as well as clinical services for aged care facilities. The company was formerly known as Medplace Limited and changed its name to Third Age Health Services Limited in April 2011. Third Age Health Services Limited was incorporated in 2010 and is based in Napier, New Zealand.
Latest available per-share figures in NZD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 04:22 PM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
Completed calendar years and any current-year payments shown separately. Current-year totals are incomplete until all payments are made.
See annual income at the current dividend rate.
Assumes the annual dividend stays unchanged. Payments follow the company’s schedule. Excludes taxes, fees and currency changes.
KEEP COMPARING
NZ$47.66+NZ$0.28 (+0.59%)
Fisher & Paykel Healthcare Corporation Limited’s quoted price sits in the upper half of its reported 52-week range, 3.97% below the high.
NZ$1.77+NZ$0.03 (+1.72%)
Ryman Healthcare Limited’s quoted price sits in the lower half of its reported 52-week range, 41.97% below the high.
NZ$1.93-NZ$0.01 (-0.26%)
Green Cross Health Limited’s quoted price sits in the upper half of its reported 52-week range, 14.22% below the high.
NZ$0.39NZ$0.00 (0.0%)
Radius Residential Care Limited’s quoted price sits in the lower half of its reported 52-week range, 20.41% below the high.
NZ$0.67NZ$0.00 (0.0%)
Promisia Healthcare Limited’s quoted price sits in the upper half of its reported 52-week range, 15.19% below the high.
NZ$0.02-NZ$0.00 (-8.0%)
BLIS Technologies Limited’s quoted price sits in the upper half of its reported 52-week range, 25.81% below the high.
NZ$0.03NZ$0.00 (0.0%)
Rua Bioscience Limited’s quoted price sits in the lower half of its reported 52-week range, 38.1% below the high.
NZ$0.01NZ$0.00 (0.0%)
TruScreen Group Limited’s quoted price sits in the lower half of its reported 52-week range, 64.0% below the high.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
